166 related articles for article (PubMed ID: 37700492)
21. Incidence and molecular epidemiology of hepatitis C virus reinfection in prisons in Catalonia, Spain (Re-HCV study).
Saludes V; Bordoy AE; Yela E; Turú E; Not A; López-Corbeto E; Egea-Cortés L; González-Candelas F; Casabona J; ; Marco A; Martró E
Sci Rep; 2023 Sep; 13(1):16012. PubMed ID: 37749145
[TBL] [Abstract][Full Text] [Related]
22. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
[TBL] [Abstract][Full Text] [Related]
23. The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017.
Crowley D; Lambert JS; Betts-Symonds G; Cullen W; Keevans M; Kelly E; Laird E; McHugh T; McKiernan S; Miggin SJ; Murphy C; Murtagh R; O'Reilly D; Tobin C; Van Hout MC
Euro Surveill; 2019 Apr; 24(14):. PubMed ID: 30968825
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.
Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P
Hepatology; 2021 Nov; 74(5):2366-2379. PubMed ID: 34105797
[TBL] [Abstract][Full Text] [Related]
25. Detection, stratification and treatment of hepatitis C-positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison.
Connoley D; Francis-Graham S; Storer M; Ekeke N; Smith C; Macdonald D; Rosenberg W
J Viral Hepat; 2020 Oct; 27(10):987-995. PubMed ID: 32449969
[TBL] [Abstract][Full Text] [Related]
26. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons.
Richter V; Goldstein L; Cohen DL; Bermont A; Zelnik Yovel D; Madar M; Rabinovitch R; Shirin H; Broide E
Sci Prog; 2022; 105(2):368504221105173. PubMed ID: 35722762
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C virus infection in South Australian prisoners: seroprevalence, seroconversion, and risk factors.
Miller ER; Bi P; Ryan P
Int J Infect Dis; 2009 Mar; 13(2):201-8. PubMed ID: 18790659
[TBL] [Abstract][Full Text] [Related]
28. Development and optimisation of a reception testing protocol designed to eliminate HCV in the UK prison population.
Mongale E; Allen S; Brew I; Ludlow-Rhodes A; Royal N; Waldron J; Alexander H; Christensen L; Dorrington K; Milner A; Missen L; Jones A; Troke PJF
JHEP Rep; 2024 Jan; 6(1):100937. PubMed ID: 38169900
[TBL] [Abstract][Full Text] [Related]
29. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran.
Hariri S; Alavi M; Roshandel G; Mohammadi Z; Fazel A; Amiriani T; Bazazan A; Motamed-Gorji N; Sohrabpour A; Merat S; Poustchi H; Malekzadeh R
Int J Drug Policy; 2021 Sep; 95():103269. PubMed ID: 33991887
[TBL] [Abstract][Full Text] [Related]
30. Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ;
J Viral Hepat; 2024 Jan; 31(1):21-34. PubMed ID: 37936544
[TBL] [Abstract][Full Text] [Related]
31. High prevalence of hepatitis C virus infection among incarcerated persons: Results from the Louisiana Hepatitis C Elimination Plan's opt-out testing program in prisons.
Irvin R; Landry G; Jones MR; James A; Schexnayder J; Rodriguez S; Wendell D; Barthe K; Britton E; LeSar K; Manogue S; Sugarman OK; Brown C; Burgess S; Mehta SH; Thomas DL; Robinson W;
J Viral Hepat; 2024 Jul; 31(7):432-435. PubMed ID: 38758571
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico.
Belaunzarán-Zamudio PF; Mosqueda-Gomez JL; Macias-Hernandez A; Sierra-Madero JG; Ahmed S; Beyrer C
PLoS One; 2017; 12(6):e0179931. PubMed ID: 28654650
[TBL] [Abstract][Full Text] [Related]
33. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.
Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C;
Int J Drug Policy; 2020 Mar; 77():102693. PubMed ID: 32045828
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
[TBL] [Abstract][Full Text] [Related]
35. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
[TBL] [Abstract][Full Text] [Related]
36. Low incidence of hepatitis C virus among prisoners in Scotland.
Taylor A; Munro A; Allen E; Dunleavy K; Cameron S; Miller L; Hickman M
Addiction; 2013 Jul; 108(7):1296-304. PubMed ID: 23297816
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C.
Marco A; Esteban JI; Solé C; da Silva A; Ortiz J; Roget M; Sarriera C; Teixidó N; Guerrero RA; Caylà JA
J Hepatol; 2013 Jul; 59(1):45-51. PubMed ID: 23523577
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis C antibody prevalence among Mexico City prisoners injecting legal and illegal substances.
Silverman-Retana O; Serván-Mori E; McCoy SI; Larney S; Bautista-Arredondo S
Drug Alcohol Depend; 2017 Dec; 181():140-145. PubMed ID: 29054033
[TBL] [Abstract][Full Text] [Related]
39. HCV micro-elimination in two prisons in Milan, Italy: A model of care.
Giuliani R; Casigliani V; Fornili M; Sebastiani T; Freo E; Arzilli G; Scardina G; Baglietto L; Tavoschi L; Ranieri R
J Viral Hepat; 2020 Dec; 27(12):1444-1454. PubMed ID: 32815623
[TBL] [Abstract][Full Text] [Related]
40. HCV spread among female incarcerated population and treatment pathways to viral elimination in Italian prison settings: clinical perspectives and medico legal aspects.
Fiore V; Rastrelli E; Madeddu G; Ranieri R; De Vito A; Giuliani R; Di Mizio G; Bolcato M; De Matteis G; Ialungo AM; Dell'Isola S; Starnini G; Babudieri S
BMC Infect Dis; 2022 Jul; 22(1):601. PubMed ID: 35799126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
